Further Update on US Regulatory Review of Roxadustat in Anemia of Chronic Kidney Disease
1 March 2021 -- AstraZeneca and FibroGen, Inc. (FibroGen) today announced that the US Food and Drug Administration (FDA) informed FibroGen that it will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the new drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Anemia | AstraZeneca | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Food and Drug Administration (FDA) | Heart | Pharmaceuticals | Urology & Nephrology